Literature DB >> 16806779

[A mild blackwater fever].

M-A Bouldouyre1, D Dia, T Carmoi, K Ba Fall, B Chevalier, J-M Debonne.   

Abstract

We report a highly probable case of moderately severe blackwater fever. A French woman, living in Guinea Bissau, was used to taking self-medication halofantrine for malaria. On this occasion, she felt unusual chills and pyrexia after a non documented bout of malaria, followed by nausea, then jaundice with dark-red urines despite another treatment with halofantrine. A sepsis was eliminated by two negatives thick peripheral blood drop examinations. Hemolysis was noted with 8.1 g/dl of hemoglobin, Coombs positive, and LDH at 1,452 IU/l, associated to renal failure with 34 ml per minute of clearance. The outcome was favourable with rehydration. Blackwater fever has been described with the three aminoalcohols, but mainly in severe presentations. Clinicians are not familiar with this disease, even though it has major therapeutic implications: quinine, halofantrine, and mefloquine become strictly contra-indicated. Moderate forms may be unknown, and this observation should be taken into account to prevent mistreatment in future patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806779     DOI: 10.1016/j.medmal.2006.03.001

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  2 in total

1.  [Blackwater fever (BWF) of late revelation about a case at the University Hospital of Dakar].

Authors:  Aliou Thiongane; Aliou Abdoulaye Ndongo; Papa Moctar Faye; Assane Sylla; Younoussa Kéïta; Djibril Boiro; Idrissa Basse; Ndèye Ramatoulaye Diagne Guèye; Ousmane Ndiaye
Journal:  Pan Afr Med J       Date:  2015-11-25

2.  Exploring association between MBL2 gene polymorphisms and the occurrence of clinical blackwater fever through a case-control study in Congolese children.

Authors:  Joseph M Bodi; Célestin N Nsibu; Roland L Longenge; Michel N Aloni; Pierre Z Akilimali; Patrick K Kayembe; Ahmeddin H Omar; Jan Verhaegen; Pierre M Tshibassu; Prosper T Lukusa; Aimé Lumaka; Kenji Hirayama
Journal:  Malar J       Date:  2020-01-15       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.